B

(redirected from Soft tissue sarcoma)
Also found in: Dictionary, Thesaurus, Medical, Legal, Acronyms, Encyclopedia, Wikipedia.

B

Fifth letter of a Nasdaq stock descriptor specifying that issue is the Class B shares of the company.

B

1. On the NASDAQ stock exchange, a symbol on the ticker board indicating that the issue being traded is class B stock. That is, B represents common stock designated by the publicly-traded company issuing it as having fewer rights than class A stock, especially fewer voting rights.

2. A low bond rating used by the S&P and Fitch credit agencies. B-rated bonds are highly speculative and are thought to contain high risk and a relatively high chance of default. Banks are not permitted to invest in B-rated bonds. See also: Junk.

B

A low, speculative grade assigned to a debt obligation by a rating agency. Such a rating indicates there is considerable uncertainty as to the ability to pay interest and repay principal over a long period.

b

Used in the dividend column of stock transaction tables in newspapers to indicate payment of a stock dividend in addition to the indicated cash dividend: 1.50b.
References in periodicals archive ?
Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: An analysis of 26,758 cases.
Conducted primarily in Europe and the United States, Study 309 was a multicenter, open-label, randomized Phase III study comparing the efficacy and safety of Halaven versus dacarbazine in 452 patients (aged 18 or over) with locally advanced, recurrent or metastatic soft tissue sarcoma (liposarcoma or leiomyosarcoma) who had disease progression following standard therapies which must have included an anthracycline and at least one other additional regimen.
DISCUSSION: A total of 35 cases of malignant soft tissue sarcomas were studied.
Prognostic significance of histologic parameters of soft tissue sarcomas.
Retroperitoneal soft tissue sarcomas can occur in any age and in our study the median age was 55 years and 7 months.
Palifosfamide, administered intravenously, is currently in a randomized, double-blinded, placebo-controlled Phase 3 trial for the treatment of metastatic soft tissue sarcoma in the front-line setting.
Companies Involved in Soft Tissue Sarcoma Therapeutics Development
Halaven was approved in the United States for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen in January 2016, and was approved in Japan for the treatment of soft tissue sarcoma in February 2016.
Malignant fibrous histiocytoma--the commonest soft tissue sarcoma or a nonexistent entity?
In the review of the Italian and German Soft Tissue Sarcoma Cooperative Group, objective response to chemotherapy was observed in only 1 of 12 patients, and the overall behavior of this tumor is found to be identical to angiosarcoma in adults.
Liposarcoma is the second most common soft tissue sarcoma, accounting for 17% of soft tissue sarcomas.
Company is taking steps toward initiating a Phase 3 trial with aldoxorubicin in soft tissue sarcoma